NICE has published a draft guideline that could change how polyendocrine metabolic ovarian syndrome, or PMOS, is recognised and monitored in the UK, recommending that people with the condition be offered an annual review and that diagnosis be made sooner. The guidance was published for public consultation on 1 July 2026 and marks the first UK-tailored guideline for the condition, which was until recently known as polycystic ovary syndrome (PCOS). ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care?utm_source=openai))
What the draft guidance says
According to NICE, the proposed annual review would help monitor symptoms, treatment and long-term health risks. The organisation said the new name better reflects the hormonal, metabolic and reproductive effects of the condition, and that the draft guidance addresses those effects comprehensively. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care?utm_source=openai))
Marie Anne Ledingham, consultant clinical advisor for women’s and reproductive health at NICE, said PMOS is a common but often overlooked condition that can have a major impact on health and wellbeing. She added that a simple annual review is an important step towards ensuring people get ongoing care and monitoring, while also supporting earlier diagnosis and management. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care?utm_source=openai))
Cost and treatment considerations
The draft guideline also includes recommendations on fertility treatment, including that IVF should be offered to those who meet the relevant access criteria in line with NICE’s fertility guideline. NICE said it does not make a recommendation about mechanical laser and light therapies for hair reduction because analysis suggests these are not cost-effective ways of improving overall health and wellbeing. The organisation estimated that recommending those therapies could cost the NHS up to £100 million per year in England. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care?utm_source=openai))
The consultation is open from 1 July to 11 August 2026, and NICE expects to publish its final PMOS guideline in December 2026. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care?utm_source=openai))
Why the timing matters
The announcement adds to a busy month for NICE’s life sciences and guidance pipeline, which has also included recent recommendations on other areas of women’s health and chronic disease. For clinicians and patients, the new PMOS draft could mean more consistent care, better awareness of a condition that is often missed, and earlier action to address longer-term risks. ([nice.org.uk](https://www.nice.org.uk/news/articles))
As the consultation period opens, NICE is inviting feedback from healthcare professionals, patients and the public before it finalises the guidance later this year. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care?utm_source=openai))
